VI Autologous Bone Marrow Transplantation.pdf - Blog Science ...

carboplatinum and ifosfamide. The second transplant will follow the first one by
only a very brief period.
In summary, high dose chemotherapy with ABMT appears to be the most
effective available therapy for patients with refractory/relapsed ovarian carcinoma,
with a response rate approximately double that of any other salvage
therapy for patients who have failed two prior regimens. In addition the 14% 1
year progression-free survival suggests that some of these remissions may be
long term, as has been the case for patients with other refractory hematologic
malignancies and solid tumors. While this therapy has not yet influenced the
clinical course in the majority of patients treated thus far, there is the potential
that a significant impact on this disease will come with the treatment of patients
earlier in their course while the disease is still sensitive to conventional drug
doses.
REFERENCES
1. Ozols RF, Young RC: Chemotherapy of ovarian cancer. Semin Oncol 18:222-232,
1991.
2. McGuire WP, Rowinsky EK, Rosenshein NB, et al: Taxol: A unique antineoplastic
agent with significant activity in advanced ovarian epithelial neoplasms. Ann Int
Med 111:273-279,1989.
3. Markman M, Hakes T, Reichman B, et al: Intraperitoneal cisplatin and cytarabine in
the treatment of refractory or recurrent ovarian carcinoma. J Clin Oncol 9:204-210,
1991.
4. Bruchner H, Wallach R: High-dose platinum for the treatment of refractory ovarian
carcinoma. Gynecol Oncol 12:64-67,1981.
5. Ozols R, Osstchega Y, Myeres C, Young RC: High-dose cisplatin in hypertonic saline
in refractory ovarian cancer. J Clin Oncol 3:1246-1250,1985.
6. DeVries EGE, Biesma B, Willemse PHB, et al: A double-blind placebo-controlled
study with granulocyte-macrophage colony-stimulating factor during chemotherapy
for ovarian carcinoma. Cancer Res 51:116-122.
7. Reed E, Janik J, Bookman M, et al: High-dose carboplatin and rGM-CSF in refractory
ovarian cancer. Proc Amer Soc Clin Oncol 9:157,1990.
8. Shea TC, Haherty M, Elias AM, et al: A phase I clinical and pharmacokinetic study of
carboplatin and autologous bone marrow support. J Clin Oncol 7:651-661,1989.
9. Mulder POM, Willemse PHB, Azalders JG, et al: High dose chemotherapy with
autologous bone marrow transplantation in patients with refractory ovarian cancer.
Eur J Cancer Clin Oncol 25:645-649,1989.
10. Viens P, Maraninchi D, Legros D, et al: High dose melphalan and autologous
marrow rescue in advanced epithelial ovarian carcinomas: A retrospective analysis
of 35 patients treated in France. Bone Marrow Transpl 5:227-233,1990.
11. Dauplat J, Legros M, Condat P, et al: High-dose melphalan and autologous bone
marrow support for the treatment of ovarian carcinoma with positive second-look
operation. Gynecol Oncol 34:294-298,1989.
12. Shpall E, Clarke-Peterson D, Soper J, et al: High-dose alkylating agent chemotherapy
with autologous bone marrow support in patients with stage ill/IV epithelial
ovarian cancer. Gynecol Oncol 38:386-391,1990.
13. Alberts D, Young L, Mason N, et al: In vitro evaluation of anticancer drugs against
ovarian cancer at concentrations achievable by intraperitoneal administration. Semin
Oncol 12:(Supp 4)38-42,1985.
14. Mulder POM, Sleijfer DT, Willemse PHB, et al: High dose cyclophosphamide or
melphalan with escalating doses of mitoxantrone and autoloaous bone marrow
396 SIXTH INTERNATIONAL SYMPOSIUM ON AUTOLOGOUS BONE MARROW TRANSPLANTATION